nicardipine has been researched along with Breast Neoplasms in 3 studies
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.
nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.
2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Enhancements of cytotoxic effects of adriamycin (ADM) and vincristine (VCR) on PC-6 (lung cancer cell line) and Hattori (breast cancer cell line) were investigated by concomitant use of a calmodulin inhibitor: nicardipine, antiplatelet agents: oxyfedrine and trimethazidine and an antihypertensive agent: trichlormethiazide." | 3.67 | [Enhanced cytotoxic effect of Adriamycin and vincristine against PC-6 (human lung cancer cell line) and Hattori (human breast cancer cell line)]. ( Inoue, K; Mitsui, I; Mukaiyama, T; Ogawa, M; Terashima, M, 1985) |
| "Among the 48 human ABC proteins, the breast cancer resistance protein (BCRP/ABCG2) has been described as a pivotal player in cancer resistance." | 2.82 | Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. ( Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Pick, A | 1 |
| Müller, H | 1 |
| Wiese, M | 1 |
| Zattoni, IF | 1 |
| Delabio, LC | 1 |
| Dutra, JP | 1 |
| Kita, DH | 1 |
| Scheiffer, G | 1 |
| Hembecker, M | 1 |
| Pereira, GDS | 1 |
| Moure, VR | 1 |
| Valdameri, G | 1 |
| Terashima, M | 1 |
| Inoue, K | 1 |
| Mukaiyama, T | 1 |
| Mitsui, I | 1 |
| Ogawa, M | 1 |
1 review available for nicardipine and Breast Neoplasms
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Dr | 2022 |
2 other studies available for nicardipine and Breast Neoplasms
| Article | Year |
|---|---|
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member | 2008 |
[Enhanced cytotoxic effect of Adriamycin and vincristine against PC-6 (human lung cancer cell line) and Hattori (human breast cancer cell line)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Small Cell; Cell Line; | 1985 |